201 Users Online
Mucopolysaccharidosis (MPS) Treatment Market
Mucopolysaccharidosis (MPS) is a group of rare, hereditary and incurable “storage diseases.” In MPS the mucopolysaccharides (sugar bound proteins) are not broken down correctly which causes products of incomplete metabolism to accumulate in the body. In MPS and other storage diseases, metabolic products that have not been eliminated have an impact on the functioning of cells, tissues and organs. The products typically accumulate, and cause symptoms, in different parts of the body.
One in 25,000 births, is estimated to be the prevalence of all forms of mucopolysaccharidosis. However, mucopolysaccharidoses, especially the milder forms of the diseases are often unrecognized, these disorders are under-diagnosed or misdiagnosed which makes it difficult to determine their true frequency in the general population.
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Increase in no. of people suffering from lysosomal diseases and high burden of rare diseases are expected to be the critical factors that may fuel the growth of the mucopolysaccharidosis (MPS) treatment market. The growing awareness regarding the novel therapies to treat mucopolysaccharidosis may boost the growth of mucopolysaccharidosis (MPS) treatment market. Moreover, the rise in research and development activities by key players for new therapeutics may also drive the growth of the market. Additionally, the growing unmet clinical needs of patients along with better treatment outcomes may also help the mucopolysaccharidosis (MPS) treatment market to grow significantly.
However, complications and severity involved in the treatment of mucopolysaccharidosis (MPS) may hamper the growth of mucopolysaccharidosis (MPS) treatment market. High cost involved in the available treatment and lack of awareness among the rural population in underdeveloped and developing countries may also result in hindering the growth of mucopolysaccharidosis (MPS) treatment market. Another factor that may restrain the growth of mucopolysaccharidosis (MPS) treatment market is the delay associated with the diagnosis of mucopolysaccharidosis.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version| Based on disease type |
|
| Based on therapy type |
|
| Based on distribution channel |
|
In the disease type segment, Mucopolysaccharidosis (MPS) type I also known as hurler’s syndrome is one of the most severe type and has a higher presence among the population compared to other types.
In the therapy type segment, the mucopolysachharidosis (MPS) treatmement market is segmented into stem cell therapy and enzyme replacement therapy.
In this distribution channel segment, Retail pharmacies may dominate the market in terms of revenue but online pharmacies are expected to experience substantial growth during the forecast period due to the growing technological developments and increasing focus on convenience.
Geographically, the global mucopolysaccharidosis (MPS) treatment market is segmented into 5 regions, which is, North America, Latin America, Asia Pacific, Europe and Middle East & Africa.
North America is expected to dominate the global market for mucopolysaccharidosis treatment during the forecast period. This can be attributed because of growing awareness among patient population regarding the advanced treatment options. Additionally, the presence of significant players and biopharmaceutical companies along with ongoing clinical trials may also drive the growth of mucopolysaccharidosis (MPS) treatment market.
Europe is expected to have the 2nd largest market for mucopolysaccharidosis (MPS) treatment. However, Asia Pacific is expected experience significant market growth during the forecast periods as a result of untapped opportunities in this region. Moreover, the launch of novel therapeutics and the rising patient population may also boost the growth of mucopolysaccharidosis (MPS) treatment market in this region.
Some of the players identified in the mucopolysaccharidosis (MPS) treatment market include:
